Table 2.
Number of events, person-years and incidence rates for composite arterial and venous thrombotic events for first, second and booster vaccinationsa
| Vaccination dose | Brand | Event | Events/100K person-years | Incidence rate | ||
|---|---|---|---|---|---|---|
| Dose 1 | No vaccination | After first dose | No vaccination | After first dose | ||
| ChAdOx1 | Arterial | 75,655/205.00 | 73,330/ 95.63 | 369.05 | 766.83 | |
| Venous | 21,230/205.00 | 17,525/ 96.09 | 103.56 | 182.39 | ||
| BNT-162b2 | Arterial | 75,655/205.00 | 57,050/ 80.99 | 369.05 | 704.38 | |
| Venous | 21,230/205.00 | 11,860/ 81.00 | 103.56 | 146.42 | ||
| mRNA-1273 | Arterial | 75,655/205.00 | 255/ 5.11 | 369.05 | 49.89 | |
| Venous | 21,230/205.00 | 190/ 5.10 | 103.56 | 37.25 | ||
| Doses 1 and 2 | After first dose | After second dose | After first dose | After second dose | ||
| ChAdOx1 | Arterial | 39,425/41.23 | 70,485/93.36 | 956.17 | 755.01 | |
| Venous | 8685/41.27 | 16,120/93.60 | 210.46 | 172.22 | ||
| BNT-162b2 | Arterial | 26,975/33.63 | 55,620/72.44 | 802.22 | 767.8 | |
| Venous | 5260/33.67 | 11,400/72.69 | 156.22 | 156.83 | ||
| mRNA-1273 | Arterial | 160/2.17 | 200/4.06 | 73.66 | 49.24 | |
| Venous | 90/2.18 | 135/4.06 | 41.37 | 33.29 | ||
| Booster | Primary course only | After booster vaccination | Primary course only | After booster vaccination | ||
| Primary course of ChAdOx1 or BNT-162b2 or mRNA-1273 | BNT-162b2 | Arterial | 157,235/182.21 | 39,735/38.72 | 862.93 | 1026.14 |
| Venous | 32,545/182.54 | 7855/ 38.97 | 178.29 | 201.54 | ||
| mRNA-1273 | Arterial | 157,235/182.22 | 3200/ 7.46 | 862.88 | 429.07 | |
| Venous | 32,545/182.56 | 760/ 7.47 | 178.27 | 101.79 | ||
| BNT-162b2 or mRNA-1273 | Arterial | 157,235/182.21 | 42,935/ 46.20 | 862.93 | 929.36 | |
| Venous | 32,545/182.58 | 8615/ 46.37 | 178.25 | 185.79 | ||
| Primary course of BNT-162b2 or mRNA-1273 | BNT-162b2 | Arterial | 70,215/80.31 | 21,425/19.04 | 874.28 | 1125.34 |
| Venous | 13,830/80.45 | 3975/19.15 | 171.91 | 207.62 | ||
| mRNA-1273 | Arterial | 70,215/80.29 | 870/ 2.23 | 874.52 | 389.78 | |
| Venous | 13,830/80.45 | 185/ 2.24 | 171.91 | 82.76 | ||
| BNT-162b2 or mRNA-1273 | Arterial | 22,300/21.25 | 874.73 | 1049.33 | 22,300/21.25 | |
| Venous | 4165/21.39 | 171.88 | 194.72 | 4165/21.39 | ||
| Primary course of ChAdOx1 | BNT-162b2 | Arterial | 87,020/101.93 | 18,310/ 19.76 | 853.73 | 926.59 |
| Venous | 18,715/102.13 | 3880/ 19.81 | 183.25 | 195.83 | ||
| mRNA-1273 | Arterial | 87,020/101.95 | 2325/ 5.21 | 853.59 | 446.61 | |
| Venous | 18,715/102.12 | 575/ 5.24 | 183.27 | 109.82 | ||
| BNT-162b2 or mRNA-1273 | Arterial | 87,020/101.95 | 20,635/ 24.94 | 853.54 | 827.32 | |
| Venous | 18,715/102.08 | 4455/ 25.08 | 183.33 | 177.61 | ||
| Primary course of BNT-162b2 | BNT-162b2 | Arterial | 70,005/76.60 | 21,415/18.78 | 913.88 | 1140.44 |
| Venous | 13,700/76.75 | 3965/18.91 | 178.51 | 209.65 | ||
| mRNA-1273 | Arterial | 70,005/76.59 | 860/ 2.02 | 914 | 426.6 | |
| Venous | 13,700/76.80 | 180/ 2.04 | 178.38 | 88.15 | ||
| BNT-162b2 or mRNA-1273 | Arterial | 70,005/76.59 | 22,275/20.79 | 913.99 | 1071.28 | |
| Venous | 13,700/76.73 | 4145/20.96 | 178.54 | 197.8 | ||
aAll counts rounded to the nearest 5 and counts less than 10 displayed as ‘10’. Bold formatting identifies headers within the table, specifically at each vaccination dose, to clearly delineate comparison groups.